

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.-35. (Cancelled)

36. (Currently Amended) A liposomal formulation, said liposomal formulation comprising a liposome having vinorelbine in solution ~~free antineoplastic drug and precipitated antineoplastic drug~~vinorelbine, wherein the precipitated ~~antineoplastic drug~~vinorelbine in said liposome is at least 50% of the total ~~antineoplastic drug~~vinorelbine, wherein said liposome comprises sphingomyelin and cholesterol at a ratio in the range of about 75/25 mol%/mol% sphingomyelin/cholesterol to about ~~35~~30/50 mol%/mol% sphingomyelin/cholesterol, ~~and wherein said antineoplastic drug is a vinca alkaloid~~and wherein the ratio of said vinoelbine to lipid is 0.1-0.5:1 (w/w).

37.-42. (Cancelled)

43. (Currently Amended) The liposomal formulation of claim ~~32 or~~ 36, wherein said liposome comprises sphingomyelin and cholesterol in a 55:45 molar ratio.

44.-65. (Cancelled)

66. (Currently Amended) The liposomal formulation of claim ~~65~~36, wherein the ratio of said ~~antineoplastic drug~~vinorelbine to said lipid is about 0.1-0.~~53~~5:1 (w/w).

67. (Currently Amended) The liposomal formulation of claim ~~32 or~~ 36, wherein said liposome comprises sphingomyelin and cholesterol in a 50:50 molar ratio.

68. (New) The liposomal formulation of claim 66, wherein the ratio of said vinorelbine to said lipid is about 0.3:1 (w/w).